HKG:2659

3 stories mentioning HKG:2659Updated just now

Every FINWIRES story that references HKG:2659, newest first.

Shanghai Bao Pharma Wins China IND Nod for BJ044 Injection

Shanghai Bao Pharmaceuticals (HKG:2659) received approval from China's National Medical Products Administration for the investigational new drug application of BJ044 injection, according to a Tuesday Hong Kong bourse filing.The company said the drug candidate is intended for the treatment of acute pancreatitis, acute exacerbation of chronic recurrent pancreatitis, and acute circulatory failure.The approval clears the company to begin clinical trials for the drug candidate in China, the filing said.

HKG:2659

Asia19d ago

Bao Pharma's IND Application Gains US FDA Approval for Bacterial Infection Therapy

Shanghai Bao Pharmaceuticals (HKG:2659) said it has received investigational new drug clearance from the U.S. Food and Drug Administration for subcutaneous infusion of BJ007, according to a Wednesday Hong Kong bourse filing.The clearance enables the company to begin a clinical trial evaluating the pharmacokinetic characteristics, absolute bioavailability, and PK/PD efficacy of BJ007 compared with intravenous ceftriaxone sodium in healthy participants, the filing said.BJ007 is a subcutaneous ceftriaxone sodium candidate being developed for the treatment of bacterial infections.

HKG:2659

Asia25d ago

Bao Pharmaceuticals' Application for Desensitization Therapy Drug Accepted in China

Shanghai Bao Pharmaceuticals' (HKG:2659) new drug application for KJ103 for injection was accepted by China's National Medical Products Administration and granted priority review status, according to a Thursday Hong Kong bourse filing.The acceptance is for use of the drug for desensitization therapy in highly sensitized kidney transplant patients.

HKG:2659

Track with the FINWIRES app suite

FolioX

Track HKG:2659 in your portfolio

WheelAI

Analyze HKG:2659 options with the wheel strategy

StockInsider

See market sentiment on HKG:2659